ニュース · QuantAbundancia

StockStory23h agoneutral

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies

StockStory7d agoneutral

Halozyme Therapeutics Earnings: What To Look For From HALO

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what to expect.

MarketBeat8d agoneutral

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO

HALO

Zacks9d agoneutral

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HALO

Zacks9d agoneutral

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks12d agobullish

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks13d agobullish

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HALO IBRX

Zacks14d agoneutral

Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

HALO

MarketBeat14d agoneutral

Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 Guidance

Halozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company’s annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc

HALO

Zacks20d agobullish

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO

Zacks22d agoneutral

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO